Found 102 clinical trials
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
www.MyelofibrosisResearch.com Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the
- 774 views
- 12 May, 2022
- 226 locations
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
www.MyelofibrosisResearch.com Myelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts
- 358 views
- 26 May, 2022
- 150 locations
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have
- 0 views
- 27 May, 2022
- 137 locations
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
- 0 views
- 17 May, 2022
- 101 locations
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis and
- 0 views
- 27 May, 2022
- 15 locations
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and …
- 0 views
- 25 May, 2022
- 16 locations
Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
People with Myelofibrosis are asked to participate in a research study being conducted by Montefiore Medical Center.
- 0 views
- 06 Aug, 2021
- 1 location
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
The purpose of this study is to evaluate the efficacy and safety of itacitinib combined with low-dose ruxolitinib or itacitinib alone in subjects with myelofibrosis.
- 172 views
- 10 May, 2022
- 9 locations
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate or High-Risk Primary or Secondary Myelofibrosis
intermediate-2 or high-risk myelofibrosis.
- 26 views
- 26 May, 2022
- 5 locations